Filing Flows › Nutra Pharma (NPHC) › Q1 2026 › vs Q4 2025
Nutra Pharma (NPHC) Q1 2026 vs Q4 2025 (quarter over quarter)
Nutra Pharma's revenue fell $2K (-6%) from $29K in Q4 2025 to $27K in Q1 2026.
Nutra Pharma, Q1 2026: revenue $27K (-63% year over year), net loss $460K, operating cash flow −$328K. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $27K | $29K | −$2K | -6% |
| Net loss | $460K | $489K | −$29K | -6% |
| Costs & expenses | $487K | $517K | −$30K | -6% |
| Operating costs | $406K | $495K | −$88K | -18% |
| Interest & other, net | $80K | $23K | $58K | +256% |
| Cost of revenue | $8K | $66K | −$58K | -87% |
| Operating cash sources | $460K | $489K | −$29K | -6% |
| Depreciation | $3K | $3K | −$71 | -3% |
| Share-based compensation | $11K | $16K | −$5K | -32% |
| Working capital & other | $118K | $250K | −$132K | -53% |
| Cash used in operations | $328K | $220K | $108K | +49% |
| Net loss absorbed | $460K | $489K | −$29K | -6% |
Questions
How much did Nutra Pharma's revenue grow quarter over quarter in Q1 2026?
Nutra Pharma's revenue fell $2K (-6%) from $29K in Q4 2025 to $27K in Q1 2026.